ArticleNature2015
A new antibiotic kills pathogens without detectable resistance.
Article in Nature, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1,011 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1,011 citing papers in PubMed, 1 synthesis or guideline pooled it, 2,388 citations in OpenAlex.
- Marine Microbes: A Source of Novel Antibiotics against Antimicrobial-resistant (AMR) Pathogens: A Systematic Review.Current drug targets · 2026Pooled it
- Natural molecule potentiates colistin efficacyVirulence · 2026Article
- Antibiotic-producing microorganisms: taxonomic diversity, screening strategies, and emerging and underexploited antibacterial targets.Archives of microbiology · 2026Review
- Predicting resistance evolution to guide antibiotic development.Nature reviews. Microbiology · 2026Review
- Discovery of potent biphenyl-macolacin derivatives through a lysine-T/CDHA iterative scanning (LTIS) strategy followed by chemical ligation-based modifications.Molecular diversity · 2026Article
- Antimicrobial Strategies in the Era of Resistance: It Is Too Early to Give Up Antibiotic Therapy.International journal of molecular sciences · 2026Review
- Article
- Epidemiology of Infections Caused by Gram-Positive Cocci-Microorganisms · 2026Review
- Acute and 28-Day Toxicity Evaluation of New Pleuromutilin Derivative 4g.Journal of applied toxicology : JAT · 2026Article
- Microbial Natural Products Targeting theMicroorganisms · 2026Review
- Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025).Medicinal research reviews · 2026Review
- When context matters: community and environmental context to elicit natural products.Essays in biochemistry · 2026Review
- Antimicrobial peptides for tuberculosis in a post-antibiotic era: from in vitro promise to therapeutic potential.npj antimicrobials and resistance · 2026Review
- Toward microbiota-friendly design and evaluation of antimicrobial peptides: a mini-review.Folia microbiologica · 2026Review
- Addressing antimicrobial resistance: Current challenges, emerging strategies, and an AI-powered, community-driven approach.PNAS nexus · 2026Review
- Breaking the antimicrobial resistance dilemma: marine natural products, a treasure trove for the development of new anti-Marine life science & technology · 2026Review
- Antibacterial drug discovery: challenges and preclinical promises from synthetic small molecules.Chemical Society reviews · 2026Review
- Integrated Genome Mining, Bacterial Co-Culture Activation, and Peptidomic Analyses Identify Antimicrobial Peptide Candidates from South American Bacteria.Antibiotics (Basel, Switzerland) · 2026Article
- Article
- Understanding the Role of Macrocycle Size and Amide Linkage in Teixobactin Analogues.Biomolecules · 2026Article
951 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
- Erratum issued
Authors and funding
21 authors at 4 institutions in 2 countries.
Funding
Abstract
Antibiotic resistance is spreading faster than the introduction of new compounds into clinical practice, causing a public health crisis. Most antibiotics were produced by screening soil microorganisms, but this limited resource of cultivable bacteria was overmined by the 1960s. Synthetic approaches to produce antibiotics have been unable to replace this platform. Uncultured bacteria make up approximately 99% of all species in external environments, and are an untapped source of new antibiotics. We developed several methods to grow uncultured organisms by cultivation in situ or by using specific growth factors. Here we report a new antibiotic that we term teixobactin, discovered in a screen of uncultured bacteria. Teixobactin inhibits cell wall synthesis by binding to a highly conserved motif of lipid II (precursor of peptidoglycan) and lipid III (precursor of cell wall teichoic acid). We did not obtain any mutants of Staphylococcus aureus or Mycobacterium tuberculosis resistant to teixobactin. The properties of this compound suggest a path towards developing antibiotics that are likely to avoid development of resistance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.